Intraductal Therapy in Breast Cancer: Current Status and Future Prospective.
Breast cancer
Ductal carcinoma in situ
Intraductal therapy
Minimally invasive
Nanomedicine
Personalized therapy
Journal
Journal of mammary gland biology and neoplasia
ISSN: 1573-7039
Titre abrégé: J Mammary Gland Biol Neoplasia
Pays: United States
ID NLM: 9601804
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
16
04
2020
accepted:
17
06
2020
pubmed:
25
6
2020
medline:
5
6
2021
entrez:
25
6
2020
Statut:
ppublish
Résumé
With our improved understanding of the biological behavior of breast cancer, minimally invasive intervention is urgently needed for personalized treatment of early disease. Intraductal therapy is one such minimally invasive approach. With the help of appropriate tools, technologies using the intraductal means of entering the ducts may be used both to diagnose and treat lesions in the mammary duct system with less trauma and at the same time avoid systemic toxicity. Traditional agents such as those targeting pathways, endocrine therapy, immunotherapy, or gene therapy can be used alone or combined with other new technologies, such as nanomaterials, through the intraductal route. Additionally, relevant mammary tumor models in rodents which reflect changes in the tumor microenvironment will help deepen our understanding of their biological behavior and heterogeneity. This article reviews the current status and future prospects of intraductal therapy in breast cancer, with emphasis on ductal carcinoma in situ.
Identifiants
pubmed: 32577880
doi: 10.1007/s10911-020-09453-4
pii: 10.1007/s10911-020-09453-4
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM